Nanopublications LDF server

Matches in Nanopublications for { ?s ?p ""Frovatriptan succinate tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia), or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions ( 5.1 Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( 5.2 History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [s ee Warnings and Precautions ( 5.4 Peripheral vascular disease [s ee Warnings and Precautions ( 5.5 Ischemic bowel disease [s ee Warnings and Precautions ( 5.5 Uncontrolled hypertension [see Warnings and Precautions ( 5.8 Recent use (i.e., within 24 hours) of another 5-HT 1 [see Drug Interactions ( 7.1 7.2 Hypersensitivity to frovatriptan succinate (angioedema and anaphylaxis seen) [s ee Warnings and Precautions ( 5.9 History of coronary artery disease or coronary artery vasospasm ( 4 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( 4 Peripheral vascular disease ( 4 Ischemic bowel disease ( 4 Uncontrolled hypertension ( 4 Recent (within 24 hours) use of treatment with another 5-HT 1 4 Hypersensitivity to frovatriptan succinate tablets (angioedema and anaphylaxis seen) ( 4"" ?g. }

• association label ""Frovatriptan succinate tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia), or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions ( 5.1 Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( 5.2 History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [s ee Warnings and Precautions ( 5.4 Peripheral vascular disease [s ee Warnings and Precautions ( 5.5 Ischemic bowel disease [s ee Warnings and Precautions ( 5.5 Uncontrolled hypertension [see Warnings and Precautions ( 5.8 Recent use (i.e., within 24 hours) of another 5-HT 1 [see Drug Interactions ( 7.1 7.2 Hypersensitivity to frovatriptan succinate (angioedema and anaphylaxis seen) [s ee Warnings and Precautions ( 5.9 History of coronary artery disease or coronary artery vasospasm ( 4 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( 4 Peripheral vascular disease ( 4 Ischemic bowel disease ( 4 Uncontrolled hypertension ( 4 Recent (within 24 hours) use of treatment with another 5-HT 1 4 Hypersensitivity to frovatriptan succinate tablets (angioedema and anaphylaxis seen) ( 4"" assertion.